Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a hold rating in a research note released on Tuesday.

Separately, HC Wainwright restated a buy rating and set a $11.00 target price on shares of Galectin Therapeutics in a research report on Tuesday, April 9th.

Galectin Therapeutics Stock Down 1.9 %

NASDAQ GALT opened at $3.05 on Tuesday. The stock has a market capitalization of $189.56 million, a P/E ratio of -4.12 and a beta of 0.72. Galectin Therapeutics has a 52-week low of $1.28 and a 52-week high of $4.27. The firm has a 50-day moving average price of $3.10 and a 200 day moving average price of $2.27.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Wednesday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, equities research analysts expect that Galectin Therapeutics will post -0.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Galectin Therapeutics

In other Galectin Therapeutics news, major shareholder James C. Czirr sold 21,323 shares of Galectin Therapeutics stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $3.06, for a total value of $65,248.38. Following the transaction, the insider now owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 4,500 shares of company stock worth $14,360 in the last quarter. 52.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Galectin Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Galectin Therapeutics by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock valued at $4,732,000 after acquiring an additional 38,037 shares in the last quarter. Wealthspire Advisors LLC lifted its holdings in shares of Galectin Therapeutics by 116.7% during the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock valued at $952,000 after acquiring an additional 214,512 shares in the last quarter. D.A. Davidson & CO. lifted its holdings in shares of Galectin Therapeutics by 15.2% during the 3rd quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock valued at $73,000 after acquiring an additional 5,000 shares in the last quarter. Solutions 4 Wealth Ltd acquired a new position in shares of Galectin Therapeutics during the 4th quarter valued at $60,000. Finally, Retirement Guys Formula LLC lifted its holdings in shares of Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock valued at $81,000 after acquiring an additional 12,232 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.